• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All.

作者信息

Moliterno David J, Smyth Susan S, Abdel-Latif Ahmed

机构信息

Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, Lexington.

Lexington VA Medical Center, Lexington, Kentucky.

出版信息

JAMA. 2020 Aug 25;324(8):747-749. doi: 10.1001/jama.2020.13094.

DOI:10.1001/jama.2020.13094
PMID:32840581
Abstract
摘要

相似文献

1
CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All.CYP2C19基因分型指导经皮冠状动脉介入治疗后的抗血小板治疗：一刀切的方法很少适用。
JAMA. 2020 Aug 25;324(8):747-749. doi: 10.1001/jama.2020.13094.
2
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.CYP2C19 基因分型指导急性冠状动脉综合征或经皮冠状动脉介入治疗患者抗血小板治疗的临床实用性。
Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647-652. doi: 10.1161/ATVBAHA.118.311963.
3
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.对接受经皮冠状动脉介入治疗的患者，利用遗传学进行抗血小板治疗的个性化用药。
Expert Rev Cardiovasc Ther. 2017 Aug;15(8):581-589. doi: 10.1080/14779072.2017.1355236. Epub 2017 Jul 19.
4
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.CYP2C19*2和CYP2C19*17基因多态性在经皮冠状动脉介入治疗后氯吡格雷反应性中起关键作用：一项药物基因组学研究。
Basic Clin Pharmacol Toxicol. 2017 Jul;121(1):29-36. doi: 10.1111/bcpt.12763. Epub 2017 Mar 14.
5
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.多中心研究：经皮冠状动脉介入治疗后实施 CYP2C19 基因指导的抗血小板治疗的结果。
JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.
6
CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.CYP2C19基因分型是伊拉克经皮冠状动脉介入治疗后服用氯吡格雷患者不良心血管结局的独立预测因素。
J Cardiovasc Pharmacol. 2018 Jun;71(6):347-351. doi: 10.1097/FJC.0000000000000577.
7
Clinical Outcomes and Sustainability of Using Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后使用基于基因型的抗血小板治疗的临床结果和可持续性。
Circ Genom Precis Med. 2018 Apr;11(4):e002069. doi: 10.1161/CIRCGEN.117.002069.
8
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.经皮冠状动脉介入治疗术后患者的基因分型、血小板活化与心血管结局：氯吡格雷抵抗难题的两个方面
Cardiology. 2017;137(2):104-113. doi: 10.1159/000457947. Epub 2017 Mar 22.
9
The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.CYP2C19 *2等位基因频率对巴勒斯坦经皮冠状动脉介入治疗后接受氯吡格雷治疗患者的临床影响。
Int J Clin Pharm. 2019 Feb;41(1):96-103. doi: 10.1007/s11096-018-00782-3. Epub 2019 Jan 17.
10
Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.基因型-表型相关性及其对急性冠状动脉综合征患者抗血小板治疗降级指导后的结局影响：TROPICAL-ACS 基因分型子研究。
Thromb Haemost. 2018 Sep;118(9):1656-1667. doi: 10.1055/s-0038-1667337. Epub 2018 Aug 13.

引用本文的文献

1
CYP2C19 point-of-care testing: where are we now and where should we go?CYP2C19即时检验：我们目前的状况及未来的方向？
Pharmacogenomics J. 2025 Jun 13;25(4):16. doi: 10.1038/s41397-025-00375-0.
2
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.基于网络药理学分析 CYP2C19 基因特性对颈动脉支架置入术后氯吡格雷抗血小板聚集的影响。
BMC Pharmacol Toxicol. 2024 Jun 6;25(1):34. doi: 10.1186/s40360-024-00750-w.
3
Implications of Pharmacogenetic Testing for Clopidogrel Therapy in a Tertiary Healthcare Hospital in North India.
印度北部一家三级医疗保健医院中氯吡格雷治疗的药物遗传学检测意义
Cureus. 2023 Jul 19;15(7):e42169. doi: 10.7759/cureus.42169. eCollection 2023 Jul.
4
ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.ABCD-GENE 评分与经皮冠状动脉介入治疗后的临床结局：来自 TAILOR-PCI 试验的见解。
J Am Heart Assoc. 2022 Feb 15;11(4):e024156. doi: 10.1161/JAHA.121.024156. Epub 2022 Feb 8.
5
Genotype-Guided P2Y Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis.经皮冠状动脉介入治疗后基于基因型的 P2Y 抑制剂治疗：贝叶斯分析。
Circ Genom Precis Med. 2021 Dec;14(6):e003353. doi: 10.1161/CIRCGEN.121.003353. Epub 2021 Oct 21.
6
Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients.16基因药物遗传学检测面板对135例患者用药管理的临床相关性
J Clin Med. 2021 Jul 21;10(15):3200. doi: 10.3390/jcm10153200.
7
Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice.临床实践中实施和管理 CYP2C19 基因检测指导氯吡格雷治疗的结果。
Eur J Clin Pharmacol. 2021 May;77(5):709-716. doi: 10.1007/s00228-020-03050-4. Epub 2020 Nov 26.